Business Wire

Samsung Electronics and TTTech Announce Strategic Partnership to Deliver Next Generation of Autonomous and Safety Technology to Automakers

Jaa

Samsung Electronics Co. Ltd. today announced a strategic partnership with TTTech, a global leader in the field of robust networking and safety controls. Along with this partnership, Samsung will also make a €75 million strategic investment in TTTech as the first investment from its recently-announced Samsung Automotive Innovation Fund (SAIF), and highlights the company’s commitment to bringing safer cars to the road and ushering in the next generation of mobility. It comes on the heels of Samsung’s $8 billion acquisition of HARMAN, a leader in connected car technology, and marks another significant step for the company in the automotive space.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170913006609/en/

Samsung Electronics and TTTech Announce Strategic Partnership to Deliver Next Generation of Autonomo ...

Samsung Electronics and TTTech Announce Strategic Partnership to Deliver Next Generation of Autonomous and Safety Technology to Automakers (Photo: Business Wire)

TTTech has been active in the automotive space for years, providing technology to a variety of manufacturers. Samsung’s future investment complements TTTech’s longstanding partnership with AUDI AG and their combined efforts in highly automated piloted driving systems for Volkswagen Group. TTTech’s safety technologies power the zFAS piloted control platform in the 2017 Audi A8.

Beyond automotive, TTTech has improved the safety and reliability of networked computer systems in the aerospace and industrial sectors, with its technologies found in the Boeing 787 Dreamliner and NASA’s Orion spacecraft.

“Automotive advances like autonomous controls and advanced driver assistance systems will have a profound impact on society—from transforming urban spaces to bringing mobility to aging populations. At Samsung, we see it as our responsibility to invest in the technologies that will revolutionize the way we live, work, and connect with one another,” said Young Sohn, President and Chief Strategy Officer of Samsung Electronics and Chairman of the Board for HARMAN. “TTTech has demonstrated a remarkable ability to innovate and build world-class technologies and platforms. This is a seminal moment for Samsung and our Automotive Innovation Fund, and we look forward to working with leading OEMs like Audi and the entire TTTech team to set a new standard for automotive-safety technology.”

“We’re excited about Samsung’s commitment to TTTech and the joint creation of new architecture for open autonomous and ADAS technologies, involving multiple key automotive players and suppliers,” said Alejandro Vukotich, Vice President Autonomous Driving of AUDI AG.

“We are very proud to have Samsung as an investor and partner in TTTech to create solutions for the next generation of highly integrated and data-intensive safety systems,” said Georg Kopetz, Member of the Board at TTTech. “Samsung brings a breadth and a depth of technologies as well as an ecosystem of partners to accelerate development for level 2 to level 5 autonomous platforms.”

“Together we will build products to support new NCAP requirements, solutions for in-vehicle infotainment systems, and new scalable architectures to support fully autonomous vehicles across various industries,” stated Stefan Poledna, Member of the Board at TTTech.

At a transformative moment for the auto industry, TTTech plans to use Samsung’s investment to accelerate the growth of its safety technology for autonomous driving and operations. The company’s collaborative and flexible technology—like its new open safety platform, MotionWise—enables OEMs and Tier-1 suppliers to accelerate the development, integration, and validation of new capabilities in their vehicles.

Together, Samsung and HARMAN are fostering the development of cutting-edge automotive safety technologies like those from TTTech, which will raise the bar for automotive safety controls and ADAS throughout the industry. HARMAN, a Tier 1 supplier, now makes TTTech’s open safety solutions available to the leading global automotive OEMs.

President Young Sohn will join Ricky Hudi, founder and managing director of Future Mobility Technologies, and other industry experts on TTTech Auto division’s new supervisory board.

About TTTech

TTTech is a global leader in the field of robust networking and safety controls. TTTech solutions improve the safety and reliability of electronic systems in the industrial and transportation sectors, with a portfolio of products that are helping to make the Industrial Internet of Things and autonomous driving a reality.

Thanks to the platform-based architecture, TTTech Auto’s production proven solutions enable simple system integration with shorter time-to-market and significant cost reductions for customers. TTTech solutions support highly scalable and modular open real-time control architectures based on Deterministic Ethernet and operates within a rich ecosystem of technology partners.

More information about TTTech and TTTech Auto is available at www.tttech.com

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.

Forward Looking Statement

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including but are not limited to, statements regarding the benefits of the strategic partnership between Samsung and TTTech Auto; the development of next-generation solutions for auto safety systems; and the ability of TTTech technology to enable OEMs and other customers to build advance auto safety solutions. These and any other forward-looking statements in this release are based on the parties’ current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, changes in the markets and the regulatory environment of automobile technology industries, difficulties in integrating technologies of the parties in the partnership, the inability of the new solutions to achieve wide market acceptance , and the ability to compete with other products in the market. The companies are providing the information in this release as of this date and do not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact information

TTTech Computertechnik AG
Marco Lehner
Marketing Communications
pr@tttech.com
or
Samsung Strategy & Innovation Center
Daniel Yoo
Sr. Manager, Communications
Dan.yoo@samsung.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13Tiedote

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme